© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 5, 384-388,
March 3, 1993
© 1993 Oxford University Press
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
Department of Medical Oncology, The University of Texas M. D. Anderson Cancer Center Houston
Community Clinical Oncology Program, The University of Texas M. D. Anderson Cancer Center Houston
Veterans Administration Hospital Houston, Tex.
Correspondence to: William K. Murphy, M.D., Section of Head, Neck and Thoracic Medical Oncology. The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 080, Houston, TX 77030.
Background: Taxol, a complex plant product (a diterpene) extracted from the bark of Taxus brevifolia, has demonstrated substantial anticancer activity in ovarian and breast cancers, malignant melanoma, and acute myelogenous leukemia. Due to allergic reactions in phase I and early phase II studies, use of a 24-hour infusion of taxol with prophylactic dexamethasone, diphenhydramine, and cimetidine has been recommended. Purpose: In this phase II study, we attempted to determine the efficacy and toxicity of taxol in patients with advanced (stage IIIB or IV) non-small-cell lung cancer who had never received chemotherapy. Methods: Patients were not excluded because of prior surgery or because of radiotherapy administered more than 4 weeks before study entry. Taxol was administered in the hospital at a dose of 200 mg/m2 as an intravenous infusion over 24 hours and repeated every 3 weeks, provided that patients had recovered from any toxic effects. Dexamethasone, cimetidine, and diphenhydramine were given before chemotherapy to prevent hypersensitivity reactions. Therapy was continued for at least two courses unless there was repid disease progression and for at least three courses if no change was observed and no grade 3 or 4 toxic effects occurred. Treatment was continued for six more courses after maximum response or for two more courses after complete remission but was discontinued if disease progressed. Results: Of the 27 patients entered in the study, 25 were assessable for toxic effects and response. One patient had an allergic reaction that was not life threatening. The overall response rate was 24% (one complete response and five partial responses). An additional seven patients (28%) had minor responses. Granulocytopenia was the dose-limiting toxic effect, and neutropenic fever occurred in eight of 118 courses. One additional patient developed neutropenic sepsis with hypotension but recovered with intensive treatment. Conclusions: Taxol appears to have activity against non-small-cell carcinoma of the lung. Implications: A phase II study combining taxol, etoposide, and cisplatin and using hematopoietic stimulating factors is now proposed. The optimal dose for combination chemotherapy has yet to be determined. An important consideration is potential cardiac effects of taxol with other drugs. [J Natl Cancer Inst 85:384–388, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer Ann. Onc., October 15, 2009; (2009) mdp352v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Rizvi, G. J. Riely, C. G. Azzoli, V. A. Miller, K. K. Ng, J. Fiore, G. Chia, M. Brower, R. Heelan, M. J. Hawkins, et al. Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2008; 26(4): 639 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Belani, S Dakhil, D. Waterhouse, C. Desch, D. Rooney, R. Clark, M. Monberg, Z Ye, and C. Obasaju Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Davies, K. Chansky, D. H.M. Lau, B. R. Leigh, L. E. Gaspar, G. R. Weiss, A. J. Wozniak, J. J. Crowley, and D. R. Gandara Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non Small-Cell Lung Cancer: SWOG S9712 J. Clin. Oncol., November 20, 2006; 24(33): 5242 - 5246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Huber, M. Flentje, M. Schmidt, B. Pollinger, H. Gosse, J. Willner, and K. Ulm Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non-Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group J. Clin. Oncol., September 20, 2006; 24(27): 4397 - 4404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Fujita, K.-i. Ito, H. Izumi, M. Kimura, M. Sano, H. Nakagomi, K. Maeno, Y. Hama, K. Shingu, S.-i. Tsuchiya, et al. Increased Nuclear Localization of Transcription Factor Y-Box Binding Protein 1 Accompanied by Up-Regulation of P-glycoprotein in Breast Cancer Pretreated with Paclitaxel Clin. Cancer Res., December 15, 2005; 11(24): 8837 - 8844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., February 20, 2005; 23(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zou, H. Fu, S. Ghosh, D. Farquhar, and J. Klostergaard Antitumor Activity of Hydrophilic Paclitaxel Copolymer Prodrug Using Locoregional Delivery in Human Orthotopic Non-Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7382 - 7391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, T. L. Madden, H. T. Tran, G. R. Blumenschein Jr, C. A. Meyers, L. F. Seabrooke, F. R. Khuri, V. K. Puduvalli, V. Allgood, H. A. Fritsche Jr, et al. Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer J. Clin. Oncol., November 15, 2002; 20(22): 4440 - 4447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, P. Berthet, J. L. Breau, P. Lianes, M. Nicholson, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann. Onc., October 1, 2002; 13(10): 1539 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, J. Boukovinas, G. Fountzilas, D. Skarlos, T. Economopoulos, D. Tsavdaridis, et al. Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial J. Clin. Oncol., September 1, 2002; 20(17): 3578 - 3585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Umemura, Y. Segawa, K. Fujiwara, I. Takata, N. Seki, Y. Tokuda, K. Eguchi, and K. Mandai A Case of Recurrent Metastatic Thymoma Showing a Marked Response to Paclitaxel Monotherapy Jpn. J. Clin. Oncol., July 1, 2002; 32(7): 262 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ogawara, M. Kawahara, S. Hosoe, S. Atagi, T. Kawaguchi, K. Okishio, N. Naka, T. Sunami, S. Mitsuoka, K. Inoue, et al. A Feasibility Study of Paclitaxel 225 mg/m2 and Carboplatin AUC = 6 in Untreated Advanced Non-small Cell Lung Cancer Patients in Japan Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Akiyama, Y. Ohe, T. Tamura, M. Sawada, A. Inoue, H. Kusaba, N. Yamamoto, I. Sekine, H. Kunitoh, T. Kodama, et al. A Dose Escalation Study of Paclitaxel and Carboplatin in Untreated Japanese Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. V. Koshkina, J. C. Waldrep, L. E. Roberts, E. Golunski, S. Melton, and V. Knight Paclitaxel Liposome Aerosol Treatment Induces Inhibition of Pulmonary Metastases in Murine Renal Carcinoma Model Clin. Cancer Res., October 1, 2001; 7(10): 3258 - 3262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Garcia, C. G. Leichman, H. J. Lenz, J. Baranda, R. Lujan, Y. Casagrande, and L. Leichman Phase II Trial of Outpatient Schedule of Paclitaxel in Patients with Previously Untreated Metastatic, Measurable Adenocarcinoma of the Stomach Jpn. J. Clin. Oncol., June 1, 2001; 31(6): 275 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kang, W. D. Figg, Y. Ando, M. V. Blagosklonny, D. Liewehr, T. Fojo, and S. E. Bates The P-Glycoprotein Antagonist PSC 833 Increases the Plasma Concentrations of 6{{alpha}}-Hydroxypaclitaxel, a Major Metabolite of Paclitaxel Clin. Cancer Res., June 1, 2001; 7(6): 1610 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kurata, T. Tamura, T. Shinkai, Y. Ohe, H. Kunitoh, T. Kodama, R. Kakinuma, T. Matsumoto, K. Kubota, H. Omatsu, et al. Phase I and Pharmacological Study of Paclitaxel Given Over 3 h with Cisplatin for Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., March 1, 2001; 31(3): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski, A. B. Sandler, L. L. Miller, P. K. Locker, C. K. Hanover, G. L. Elfring, V. K. Israel, N. Pirotta, and R. B. Natale Phase I Trial of the Combination of Irinotecan, Paclitaxel, and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2001; 19(4): 1078 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Perez-Soler, B. Kemp, Q. P. Wu, L. Mao, J. Gomez, A. Zeleniuch-Jacquotte, H. Yee, J. S. Lee, J. Jagirdar, and Y. H. Ling Response and Determinants of Sensitivity to Paclitaxel in Human Non-Small Cell Lung Cancer Tumors Heterotransplanted in Nude Mice Clin. Cancer Res., December 1, 2000; 6(12): 4932 - 4938. [Abstract] [Full Text]
|
|
|
|
|
|
U. Gatzemeier, J. von Pawel, M. Gottfried, G. P. M. t. Velde, K. Mattson, F. DeMarinis, P. Harper, F. Salvati, G. Robinet, A. Lucenti, et al. Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3390 - 3399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Berthelot, B. P. Will, W. K. Evans, D. Coyle, C. C. Earle, and L. Bordeleau Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 16, 2000; 92(16): 1321 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Belani Combined Modality Therapy for Unresectable Stage III Non-Small Cell Lung Cancer : New Chemotherapy Combinations Chest, April 1, 2000; 117 (2009): 127S - 132S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer Chest, April 1, 2000; 117 (2009): 144S - 151S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Akerley III Paclitaxel in Advanced Non-Small Cell Lung Cancer : An Alternative High-Dose Weekly Schedule Chest, April 1, 2000; 117 (2009): 152S - 155S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, M. Jiroutek, and D. Johnson Comparison of Survival and Quality of Life in Advanced Non-Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial J. Clin. Oncol., February 1, 2000; 18(3): 623 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Nicoletti, T. Colombo, C. Rossi, C. Monardo, S. Stura, M. Zucchetti, A. Riva, P. Morazzoni, M. B. Donati, E. Bombardelli, et al. IDN5109, a Taxane with Oral Bioavailability and Potent Antitumor Activity Cancer Res., February 1, 2000; 60(4): 842 - 846. [Abstract] [Full Text]
|
|
|
|
|
|
L. Kraus-Berthier, M. Jan, N. Guilbaud, M. Naze, A. Pierré, and G. Atassi Histology and Sensitivity to Anticancer Drugs of Two Human Non-Small Cell Lung Carcinomas Implanted in the Pleural Cavity of Nude Mice Clin. Cancer Res., January 1, 2000; 6(1): 297 - 304. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer Oncologist, October 1, 1999; 4(5): 408 - 416. [Abstract] [Full Text]
|
|
|
|
|
|
P. G. Rose, J. A. Blessing, D. M. Gershenson, and R. McGehee Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study J. Clin. Oncol., September 1, 1999; 17(9): 2676 - 2676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Frasci, N. Panza, P. Comella, G. P. Nicolella, M. Natale, L. Manzione, D. Bilancia, R. Cioffi, L. Maiorino, G. De Cataldis, et al. Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase I-II Study J. Clin. Oncol., August 1, 1999; 17(8): 2316 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Bhalla, G. N. Kumar, U. K. Walle, A. M. Ibrado, T. Javed, R. K. Stuart, C. Reed, S. G. Arbuck, and T. Walle Phase I and Pharmacologic Study of a 3-Hour Infusion of Paclitaxel followed by Cisplatinum and 5-Fluorouracil in Patients with Advanced Solid Tumors Clin. Cancer Res., July 1, 1999; 5(7): 1723 - 1730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Monzo, R. Rosell, J. J. Sanchez, J. S. Lee, A. O'Brate, J. L. Gonzalez-Larriba, V. Alberola, J. C. Lorenzo, L. Nunez, J. Y. Ro, et al. Paclitaxel Resistance in Non-Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations J. Clin. Oncol., June 1, 1999; 17(6): 1786 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al. Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial J. Clin. Oncol., March 1, 1999; 17(3): 914 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani, C. M. Kearns, E. G. Zuhowski, K. Erkmen, D. Hiponia, D. Zacharski, C. Engstrom, R. K. Ramanathan, M. J. Capozzoli, J. Aisner, et al. Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 676 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer and D. S. Ettinger The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy Oncologist, April 1, 1998; 3(2): 67 - 85. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. K. Rowinsky and R. C. Donehower Paclitaxel (Taxol) N. Engl. J. Med., April 13, 1995; 332(15): 1004 - 1014. [Full Text] [PDF]
|
|